MIB-1 and p53 expression in radiotherapy-resistant T1aN0M0 glottic squamous cell carcinoma

Motamed, M.; Banerjee, Anirban; Bradley, P.J.; Powe, Desmond G.

doi:10.1046/j.1365-2273.2001.00461.x

Cited by 8 publications

(7 citation statements)

References 26 publications

(45 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of those, nine did not find a significant association between Ki-67 PI and LC after RT. [6][7][8][9][10][11]13,14 Two subgroup analyses in one study showed a negative association between high Ki-67 and LC in both a cohort treated with accelerated RT (ART) and in a combined cohort treated with either ART or conventional RT (HR 2.66; 95% CI 1.17-6.08 and HR 5.11;…”

Section: Discussionmentioning

confidence: 99%

“…Therefore, Ki‐67 is an ideal marker to quantify the relative amount of proliferative neoplastic cells within tumour tissue, defined as the Ki‐67 proliferation index (Ki‐67 PI). However, the results of earlier studies investigating the relationship between the Ki‐67 PI, local control (LC) and survival after primary RT in laryngeal squamous cell cancer (LSCC) are not unambiguous, as shown in Table . Possible explanations for these differences are variations in patient group factors, immunostaining and scoring‐related factors …”

Section: Introductionmentioning

confidence: 98%

“…However, the results of earlier studies investigating the relationship between the Ki-67 PI, local control (LC) and survival after primary RT in laryngeal squamous cell cancer (LSCC) are not unambiguous, as shown in Table 1. [4][5][6][7][8][9][10][11][12][13][14] Possible explanations for these differences are variations in patient group factors, immunostaining and scoring-related factors. [15][16][17] The aim of this study was to assess the value of Ki-67 PI in predicting LC and disease-specific survival (DSS) after primary RT in a well-defined consecutive series of patients with early-stage (T1-T2) LSCC.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Standardised Ki‐67 proliferation index assessment in early‐stage laryngeal squamous cell carcinoma in relation to local control and survival after primary radiotherapy

Kop

Bock

Noordhuis

et al. 2019

Clinical Otolaryngology

View full text Add to dashboard Cite

Over the years, many studies have been conducted to identify prognostic and predictive markers for head and neck squamous cell carcinoma (HNSCC). 1 To date, prognostic markers such as age, TNM-stage and histological type determine decision-making regarding the most optimal treatment strategy. In oncogenesis, cell proliferation is one of the most essential biological processes and may therefore be a strong predictive and prognostic marker. 2 Ki-67 is a nuclear marker that is present in all phases of the cell cycle but absent in resting cells (G0 phase). 3 Therefore, Ki-67 is an ideal marker to quantify the relative amount of proliferative neoplastic cells within tumour tissue, defined

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 98%

mentioning

confidence: 99%

See 1 more Smart Citation

Standardised Ki‐67 proliferation index assessment in early‐stage laryngeal squamous cell carcinoma in relation to local control and survival after primary radiotherapy

Kop

Bock

Noordhuis

et al. 2019

Clinical Otolaryngology

View full text Add to dashboard Cite

show abstract

“…These include, among others, activation of various oncogenes (Ras , ( 4,5 ) Myc, ( 6 ) epidermal growth factor receptor, ( 7 ) and cyclin D1 ( 8 ) ), and tumor suppressor gene inactivation (P53 and p16). ( 9,10 ) However, accurate and reliable biomarkers that serve for prognosis have yet to be identified.…”

mentioning

confidence: 99%

DJ‐1: A novel independent prognostic marker for survival in glottic squamous cell carcinoma

et al. 2010

View full text Add to dashboard Cite

DJ-1 is frequently overexpressed in a large variety of solid tumors, but the DJ-1 expression in laryngeal squamous cell cancer and its clinical ⁄ prognostic significance is unclear. We aimed to evaluate DJ-1 protein expression in glottic squamous cell carcinoma (GSCC) and to correlate this with clinicopathological data including patient survival. The expression of DJ-1 in GSCCs (60) and adjacent normal tissue (44) was assessed by immunohistochemistry and western blot analysis. In addition, the role of DJ-1 was investigated in tumorigenesis by transfecting DJ1-specific siRNA into laryngeal squamous cell carcinoma (LSCC) Hep-2 cells. Our data showed that positive expression of DJ-1 was found in 85% of GSCCs. In univariate survival analysis of the GSCC cohorts, a highly significant association between DJ-1 expression with shortened patient overall survival (5-year survival rate 92.9% vs 66.6%; P = 0.001; log rank test) was demonstrated. In multivariate analyses, DJ-1, tumor grading, and pT status were significant prognostic parameters for shortened patient overall survival. Furthermore, siRNA targeting DJ-1 can effectively inhibit DJ-1 expression, resulting in enhanced apoptosis and less proliferation of Hep-2 cells. We concluded that DJ-1 overexpression might be a novel independent molecular marker for poor prognosis (shortened overall survival) of patients with GSCC. (Cancer Sci 2010; 101: 1320-1325 L aryngeal carcinoma accounts for approximately 2.4% of new malignancies worldwide every year, of which over 95% are of the squamous cell carcinoma.(1,2) Glottic squamous cell carcinoma (GSCC) is the most common type of laryngeal cancer. Patients with GSCC often display considerable variability in survival.(3) It is of general importance to predict the biology of the tumor and, thus, the course of the disease in the individual patient to ensure adequate therapy and patient surveillance. Conventional prognostic and predictive markers for GSCC are nodal status, tumor grade, tumor status, and tumor type.(3) Additionally, molecular markers are being sought and established to allow for a refined classification of prognosis, especially in patient subgroups whose outcome can only insufficiently be predicted by conventional parameters. These include, among others, activation of various oncogenes (Ras, (4,5) Myc,epidermal growth factor receptor,and cyclin D1 (8) ), and tumor suppressor gene inactivation (P53 and p16).(9,10) However, accurate and reliable biomarkers that serve for prognosis have yet to be identified.DJ-1 encodes a conserved protein belonging to the ThiJ ⁄ PfpI ⁄ DJ-1 superfamily.(11) The THEMATICS (theoretical microscopic titration curves) predicted eight DJ-1 family members and three different probable functional classes.(12) The exact molecular function of DJ-1 is still unclear although increasing evidence suggests that DJ-1 plays a role in cancer cell lines to protect against stress (13)(14)(15) and affects cell survival by modulating the phosphorylation status of protein kinase B (PKB) ⁄ Akt, (16)(17)(18)...

show abstract

“…80,81 Toxicity patterns also appear to have a genetic basis and, in some cases, have been mapped to specific chromosomes or to cytokine misregulation. 82 We hypothesize that by using such genetic markers together with circulating cytokine levels, it will be possible to identify patients at risk for various levels of toxicity.…”

Section: Molecular Markersmentioning

confidence: 99%

Report from the Radiation Oncology Committee of the Southwest Oncology Group (SWOG)

Okunieff¹,

Meyn²,

Teicher³

et al. 2003

American Journal of Clinical Oncology

View full text Add to dashboard Cite

To achieve the ultimate goal of cancer treatment, which is 100% cancer control with negligible toxicity, the therapeutic window must be enlarged, allowing for higher doses of beneficial treatments with reduced toxicity. The advent of image- and metabolism-guided therapy offers the best opportunity to date for combining modern radiation targeting and imaging techniques. Indeed, for the first time, it is reasonable to locally target metastatic disease with the goal of sterilization. Combining these focal radiation techniques with novel targeted antiproliferative agents and full-dose classic cytotoxic chemotherapy will become more effective as we learn to use these compounds in a less systemically toxic manner and as radiation fields become more defined. In addition, increasing numbers of biologic modifiers of normal tissue response are becoming available, and they suggest great promise for decreasing the normal tissue toxicity resulting from both radiation and chemotherapy treatments. Thus, radiation metastectomy for gross metastases, used together with systemic control of micrometastatic disease, may yield improved survival rates. This hypothesis is ready for testing in cancers of the breast, prostate, colon, and in sarcomas. Enlarging the therapeutic window is a major goal that would allow for an increasingly favorable therapeutic gain.

show abstract

MIB-1 and p53 expression in radiotherapy-resistant T1aN0M0 glottic squamous cell carcinoma

Cited by 8 publications

References 26 publications

Standardised Ki‐67 proliferation index assessment in early‐stage laryngeal squamous cell carcinoma in relation to local control and survival after primary radiotherapy

Standardised Ki‐67 proliferation index assessment in early‐stage laryngeal squamous cell carcinoma in relation to local control and survival after primary radiotherapy

DJ‐1: A novel independent prognostic marker for survival in glottic squamous cell carcinoma

Report from the Radiation Oncology Committee of the Southwest Oncology Group (SWOG)

Contact Info

Product

Resources

About